This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …

Objective: To revise and expand the 1996 Osteoporosis Society of Canada clinical practice
guidelines for the management of osteoporosis, incorporating recent advances in diagnosis …

Systemic corticosteroids play an integral role in the management of many inflammatory and
immunologic conditions, but these agents are also associated with serious risks …

Background Osteoporosis is a common complication of long-term glucocorticoid therapy for
which there is no well-proved preventive or restorative treatment. Methods We carried out …

Background Bisphosphonates are effective agents for the management of osteoporosis.
Their low bioavailability and low potency necessitate frequent administration on an empty …

Since the publication of the Osteoporosis Canada guide-lines in 2002, there has been a
paradigm shift in the prevention and treatment of osteoporosis and fractures. 1, 2 The focus …

Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The
monoclonal antibody romosozumab binds to sclerostin and increases bone formation …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

Denosumab is a fully human monoclonal antibody that inhibits bone resorption by
neutralizing RANKL, a key mediator of osteoclast formation, function, and survival. This …

Background: The Medical Outcomes Study 36-item Short Form (SF-36) is a widely used
measure of health-related quality of life. Normative data are the key to determining whether …